The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Risk-adapted management strategies for smoldering myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the benefits of risk-adapted management strategies for smoldering myeloma. Dr Mateos talks on the identification of low-risk smoldering myeloma, where patients can be reassessed annually, and reports that intermediate-risk patients can be assessed every four to six months without treatment. For high-risk patients, Dr Mateos highlights two studies which demonstrated a benefit of early treatment with lenalidomide. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.
